Vici Health Sciences

Vici Health Sciences is a pharmaceutical research and development organization headquartered in Elkridge, MD, operating as a full-service contract development and manufacturing organization (CDMO) and contract research organization (CRO) serving the peptide industry and broader pharmaceutical sector. With a comprehensive suite of capabilities spanning drug formulation, analytical testing, cGMP manufacturing, and FDA regulatory consulting, Vici Health Sciences has positioned itself as a credible and technically sophisticated partner for pharmaceutical and biotech companies navigating the complex landscape of peptide-based drug development. Their Maryland facility brings together scientific expertise and industry-grade infrastructure to support projects from early-stage research through clinical supply and commercial readiness.

As a research laboratory in Elkridge, Vici Health Sciences offers an extensive range of services tailored to the demands of modern peptide research and pharmaceutical development. Their formulation development capabilities encompass oral solids, oral liquids, buccal, topical, injectable, and ophthalmic dosage forms, along with specialized bioavailability enhancement strategies — a particularly relevant competency for peptide compounds known for their complex absorption profiles. On the analytical side, the team provides identity and assay testing, impurity profiling, method development and validation, content uniformity, dissolution testing, and stability storage and testing programs. Research labs engaged in peptide characterization will find their analytical services especially valuable for generating the rigorous data packages required for regulatory submissions and quality documentation.

Vici Health Sciences serves clients on a national scale, making their research laboratory in Elkridge a resource accessible to pharmaceutical sponsors, biotech startups, academic institutions, and compounding pharmacy networks across the United States. Their contract laboratory services extend into custom synthesis, clinical supply manufacturing, clinical packaging, nutraceutical and dietary supplement manufacturing, and commercial-scale oral solids and oral liquids manufacturing. This breadth of capability allows research labs and development teams to consolidate multiple stages of their peptide programs under one trusted partner, reducing handoff risk and streamlining project timelines from the bench to the clinic.

Industry professionals evaluating research labs for peptide development partnerships should prioritize organizations that demonstrate adherence to cGMP standards, rigorous analytical method validation practices, and a proven track record with FDA regulatory pathways. Vici Health Sciences addresses these expectations through its regulatory services division, which supports 505(b)(2) strategy and consulting, as well as pre-IND, IND, and NDA submissions — providing the scientific and strategic guidance necessary to move peptide compounds through the regulatory process with confidence. A commitment to quality systems, validated testing methodologies, and transparent documentation practices are hallmarks of any dependable pharmaceutical research and manufacturing partner, and these are central to the operational philosophy reflected in the services Vici Health Sciences provides.

Industry professionals, pharmaceutical sponsors, and peptide researchers interested in learning more about partnering with a research laboratory in Elkridge that offers end-to-end CDMO and CRO capabilities are encouraged to reach out to Vici Health Sciences directly. Whether your organization requires early-phase formulation work, analytical characterization of peptide compounds, regulatory strategy support, or clinical supply manufacturing, their team is equipped to discuss how their services align with your program's specific needs. Contact Vici Health Sciences at (410) 379-1500 or visit their website to explore their full capabilities and begin a conversation about your next research or development initiative.